Key Highlights
- Exclusive partnership: Single Pass collaborates with Mermaid Medical Group for the US distribution of its innovative biopsy closure device.
- Advanced technology: The device offers a safe, efficient method for closing biopsy sites, reducing complications, and promoting faster recovery.
- Expanded access: Mermaid Medical Group’s extensive network ensures widespread availability of this cutting-edge device across the US.
Source: PR Newswire
Notable Quotes
- “We are thrilled to partner with Mermaid Medical Group for the exclusive distribution of our biopsy closure device in the United States,” – Bill Colone, CEO at Single Pass
- “This partnership reflects our dedication to providing healthcare professionals with innovative solutions that enhance patient care,” – Marcus Nielsen, General Manager at Mermaid Medical Group
SoH's Take
This strategic alliance between Single Pass and Mermaid Medical Group is a significant leap forward in the field of interventional medicine. The collaboration not only underscores the commitment of both companies to advance patient care but also highlights the growing importance of innovative medical technologies in improving procedural outcomes. By leveraging Mermaid Medical Group’s robust distribution network, Single Pass’s biopsy closure device is poised to become a game-changer in the U.S. healthcare market. This partnership is a testament to the synergies that can be achieved when industry leaders combine their strengths, ultimately benefiting patients and healthcare providers alike. The role of Scan MedPartners in facilitating this partnership also exemplifies the critical importance of strategic networking in the medical technology sector.
